Reduction of visible bone metastases by clodronate therapy in breast cancer

European Journal of Gynaecological Oncology

Volumn 22, Issue 3, 2001, Pages 215-216

  Tjalma, W A ^a   Buytaert, P M ^a   Berneman, Z N ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bone metastases; Breast cancer; Clodronate therapy; Reduction

Indexed keywords

AMSACRINE; AZACITIDINE; CLODRONIC ACID; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; MITOXANTRONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE ATROPHY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CONFERENCE PAPER; FEMALE; HUMAN; MASTECTOMY; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLODRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0034880885     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Medical treatment of bone metastases
2. Biology of bone metastases
3. The clinical course of bone metastases from breast cancer
4. Biphosphonates in the prevention and treatment of metastatic bone disease
5. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
6. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
7. Oral clodronate and reduction in loss of bone mineral denisty in women with operable primary breast cancer
8. Clinical decision-making in early breast cancer
9. Biphosphonates: Preclinical aspects and use in osteoporosis
10. Reduction in new metastases in breast cancer with adjuvant clodronate treatment